APIDRA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for APIDRA (APIDRA).
Insulin glulisine is a rapid-acting insulin analog that lowers blood glucose by binding to and activating insulin receptors on cells, facilitating glucose uptake into muscle and adipose tissue, and inhibiting hepatic glucose production.
| Metabolism | Primarily metabolized by liver and kidney via enzymatic degradation; cytochrome P450 enzymes are not involved. |
| Excretion | Primarily renal; ~60% of a dose is excreted as metabolites and unchanged drug in urine. Fecal elimination is minimal (<10%). |
| Half-life | Terminal elimination half-life is approximately 30 minutes. This short half-life allows for flexible dosing and rapid clearance, but necessitates multiple daily injections or continuous subcutaneous insulin infusion. |
| Protein binding | ~60% bound to serum proteins (primarily albumin). |
| Volume of Distribution | 0.13-0.21 L/kg (for insulin glulisine). This small Vd indicates limited extravascular distribution, consistent with action in the vascular compartment. |
| Bioavailability | Subcutaneous: approximately 70% (range 60-85%). |
| Onset of Action | Subcutaneous: 15-30 minutes. Faster than regular human insulin due to rapid absorption. |
| Duration of Action | Subcutaneous: 3-5 hours. Shorter duration than regular human insulin, reducing risk of late postprandial hypoglycemia. |
Subcutaneous injection 0.2-0.4 units/kg once daily or divided twice daily, or as part of basal-bolus regimen with 50-70% of total daily insulin as prandial insulin given within 15 minutes before or within 20 minutes after starting a meal.
| Dosage form | INJECTABLE |
| Renal impairment | For GFR 30-50 mL/min: reduce dose by 25%. For GFR 15-29 mL/min: reduce dose by 50%. For GFR <15 mL/min: avoid use or reduce dose by 75% with close monitoring. |
| Liver impairment | Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 25%. Child-Pugh Class C: reduce dose by 50% and monitor glucose closely. |
| Pediatric use | Children ≥6 years: 0.25-0.5 units/kg/day total insulin, with 50-70% as prandial dose given subcutaneously within 15 minutes before or 20 minutes after meals. Dose adjusted based on blood glucose levels and HbA1c. |
| Geriatric use | Start at 50% of adult dose (e.g., 0.1-0.2 units/kg/day) and titrate slowly, with less aggressive targets to avoid hypoglycemia. Individualize based on renal function and frailty. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for APIDRA (APIDRA).
| Breastfeeding | Insulin glulisine is a protein that is likely degraded in the infant's gastrointestinal tract. No M/P ratio available; minimal transfer into breast milk is expected. Compatible with breastfeeding with monitoring of infant blood glucose. |
| Teratogenic Risk | Insulin glulisine (APIDRA) does not cross the placenta in significant amounts. No teratogenic effects are known, but uncontrolled maternal diabetes increases fetal risks. First trimester: risk of malformations related to hyperglycemia. Second and third trimesters: risk of macrosomia, polyhydramnios, neonatal hypoglycemia. |
■ FDA Black Box Warning
Never share an Apidra SoloStar prefilled pen or cartridge between patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
| Common Effects | Hypoglycemia low blood glucose level Allergic reaction Injection site reactions pain swelling redness Lipodystrophy skin thickening or pits at the injection site Itching Rash Upper respiratory tract infection |
| Serious Effects |
["Hypoglycemia (during episodes)","Hypersensitivity to insulin glulisine or any product excipients"]
| Precautions | ["Hypoglycemia is the most common adverse reaction; caution in patients with hepatic or renal impairment","Changes in insulin regimen may affect glycemic control; dose adjustments required with concomitant use of thiazolidinediones (TZDs)","Risk of heart failure when used in combination with TZDs","Hypokalemia may occur; monitor potassium levels in patients at risk","Injection site reactions or lipodystrophy may occur; rotate injection sites","Accidental mix-ups between different insulin products may occur; verify product before administration"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal blood glucose, HbA1c, fetal growth (ultrasound), and fetal well-being (nonstress test, biophysical profile) as per standard diabetes in pregnancy protocols. |
| Fertility Effects | No direct effects on fertility. Uncontrolled diabetes can impair fertility due to hormonal imbalances. Improved glycemic control restores normal reproductive function. |
| Food/Dietary | No specific food restrictions, but carbohydrate intake timing and amount should be consistent to match insulin action. Alcohol may cause unpredictable blood glucose effects, increasing hypoglycemia risk. |
| Clinical Pearls | APIDRA (insulin glulisine) is a rapid-acting insulin analog with onset of action ~15 minutes, peak ~30-90 minutes, and duration 3-5 hours. Administer within 15 minutes before or within 20 minutes after starting a meal. Do not mix with insulins other than NPH. Use with caution in patients with renal or hepatic impairment. May cause hypokalemia; monitor potassium levels. |
| Patient Advice | Do not use if solution is cloudy or contains particles. · Rotate injection sites to prevent lipodystrophy. · Avoid alcohol consumption as it may increase risk of hypoglycemia. · Monitor blood glucose regularly and adjust doses as directed. · Carry a fast-acting carbohydrate source for hypoglycemia treatment. |